161 related articles for article (PubMed ID: 12077389)
1. Neurodegeneration. A glutamine-rich trail leads to transcription factors.
Freiman RN; Tjian R
Science; 2002 Jun; 296(5576):2149-50. PubMed ID: 12077389
[No Abstract] [Full Text] [Related]
2. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
[TBL] [Abstract][Full Text] [Related]
3. Interaction of Huntington disease protein with transcriptional activator Sp1.
Li SH; Cheng AL; Zhou H; Lam S; Rao M; Li H; Li XJ
Mol Cell Biol; 2002 Mar; 22(5):1277-87. PubMed ID: 11839795
[TBL] [Abstract][Full Text] [Related]
4. Biomedicine. Huntingtin--profit and loss.
Trottier Y; Mandel JL
Science; 2001 Jul; 293(5529):445-6. PubMed ID: 11463904
[No Abstract] [Full Text] [Related]
5. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice.
Yu ZX; Li SH; Nguyen HP; Li XJ
Hum Mol Genet; 2002 Apr; 11(8):905-14. PubMed ID: 11971872
[TBL] [Abstract][Full Text] [Related]
6. Polyglutamine disease: acetyltransferases awry.
Hughes RE
Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
[TBL] [Abstract][Full Text] [Related]
7. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
8. Neurodegeneration. Huntington's research points to possible new therapies.
Marx J
Science; 2005 Oct; 310(5745):43-5. PubMed ID: 16210515
[No Abstract] [Full Text] [Related]
9. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
Ross CA
Neuron; 1997 Dec; 19(6):1147-50. PubMed ID: 9427237
[No Abstract] [Full Text] [Related]
10. New light on polyglutamine neurodegenerative disorders: interference with transcription.
Néri C
Trends Mol Med; 2001 Jul; 7(7):283-4. PubMed ID: 11425622
[No Abstract] [Full Text] [Related]
11. Huntington's disease--making connections.
Greenamyre JT
N Engl J Med; 2007 Feb; 356(5):518-20. PubMed ID: 17267914
[No Abstract] [Full Text] [Related]
12. PGC-1alpha, a new therapeutic target in Huntington's disease?
McGill JK; Beal MF
Cell; 2006 Nov; 127(3):465-8. PubMed ID: 17081970
[TBL] [Abstract][Full Text] [Related]
13. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains.
Dennig J; Beato M; Suske G
EMBO J; 1996 Oct; 15(20):5659-67. PubMed ID: 8896459
[TBL] [Abstract][Full Text] [Related]
14. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.
Nucifora FC; Sasaki M; Peters MF; Huang H; Cooper JK; Yamada M; Takahashi H; Tsuji S; Troncoso J; Dawson VL; Dawson TM; Ross CA
Science; 2001 Mar; 291(5512):2423-8. PubMed ID: 11264541
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
[TBL] [Abstract][Full Text] [Related]
16. Huntington's disease.
Davies S; Ramsden DB
Mol Pathol; 2001 Dec; 54(6):409-13. PubMed ID: 11724916
[TBL] [Abstract][Full Text] [Related]
17. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner.
Benn CL; Sun T; Sadri-Vakili G; McFarland KN; DiRocco DP; Yohrling GJ; Clark TW; Bouzou B; Cha JH
J Neurosci; 2008 Oct; 28(42):10720-33. PubMed ID: 18923047
[TBL] [Abstract][Full Text] [Related]
18. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
Bates EA; Victor M; Jones AK; Shi Y; Hart AC
J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
20. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets.
Zhai W; Jeong H; Cui L; Krainc D; Tjian R
Cell; 2005 Dec; 123(7):1241-53. PubMed ID: 16377565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
